JP2012021005A5 - - Google Patents

Download PDF

Info

Publication number
JP2012021005A5
JP2012021005A5 JP2011177316A JP2011177316A JP2012021005A5 JP 2012021005 A5 JP2012021005 A5 JP 2012021005A5 JP 2011177316 A JP2011177316 A JP 2011177316A JP 2011177316 A JP2011177316 A JP 2011177316A JP 2012021005 A5 JP2012021005 A5 JP 2012021005A5
Authority
JP
Japan
Prior art keywords
equol
medicament
androgen
androgen receptor
providing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011177316A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012021005A (ja
JP5535999B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012021005A publication Critical patent/JP2012021005A/ja
Publication of JP2012021005A5 publication Critical patent/JP2012021005A5/ja
Application granted granted Critical
Publication of JP5535999B2 publication Critical patent/JP5535999B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2011177316A 2002-10-29 2011-08-12 アンドロゲンによって仲介される疾患を治療するためのエクオールの使用 Expired - Fee Related JP5535999B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42246902P 2002-10-29 2002-10-29
US60/422,469 2002-10-29

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2004548591A Division JP4889944B2 (ja) 2002-10-29 2003-10-29 アンドロゲンによって仲介される疾患を治療するためのエクオールの使用

Publications (3)

Publication Number Publication Date
JP2012021005A JP2012021005A (ja) 2012-02-02
JP2012021005A5 true JP2012021005A5 (cg-RX-API-DMAC7.html) 2012-10-11
JP5535999B2 JP5535999B2 (ja) 2014-07-02

Family

ID=32230355

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004548591A Expired - Lifetime JP4889944B2 (ja) 2002-10-29 2003-10-29 アンドロゲンによって仲介される疾患を治療するためのエクオールの使用
JP2011177316A Expired - Fee Related JP5535999B2 (ja) 2002-10-29 2011-08-12 アンドロゲンによって仲介される疾患を治療するためのエクオールの使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2004548591A Expired - Lifetime JP4889944B2 (ja) 2002-10-29 2003-10-29 アンドロゲンによって仲介される疾患を治療するためのエクオールの使用

Country Status (6)

Country Link
US (7) US20060122262A1 (cg-RX-API-DMAC7.html)
EP (1) EP1569636B1 (cg-RX-API-DMAC7.html)
JP (2) JP4889944B2 (cg-RX-API-DMAC7.html)
AU (1) AU2003286781B2 (cg-RX-API-DMAC7.html)
CA (1) CA2504682A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004039327A2 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003259220C1 (en) 2002-07-24 2017-08-24 Australian Health & Nutrition Association Limited Compositions and products containing enantiomeric equol, and methods for their making
US8668914B2 (en) * 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
EP1569636B1 (en) 2002-10-29 2017-12-13 Colorado State University Research Foundation Use of equol for treating androgen mediated diseases
WO2008020853A1 (en) * 2006-08-18 2008-02-21 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
ES2417481T3 (es) * 2003-06-30 2013-08-08 Otsuka Pharmaceutical Co., Ltd. Composición que contiene una bacteria del ácido láctico que produce ecuol
EP1740191A4 (en) * 2004-04-28 2008-07-30 Univ Brigham Young USE OF EQUOL FOR THE TREATMENT OF SKIN DISEASES
JP4808715B2 (ja) * 2005-07-29 2011-11-02 カルピス株式会社 更年期障害予防・改善剤および機能性飲食品
US7528267B2 (en) 2005-08-01 2009-05-05 Girindus America, Inc. Method for enantioselective hydrogenation of chromenes
NL1030571C2 (nl) * 2005-12-01 2006-04-27 Sara Lee De Nv Geurafgiftesysteem.
US8680140B2 (en) * 2006-08-02 2014-03-25 University Of Southern California Phytoestrogenic formulations for alleviation or prevention of menopausal symptoms
US20100280231A1 (en) * 2007-04-09 2010-11-04 Masayuki Nakano Whitening agent comprising equol or its saccharide derivative as an effective ingredient
JP5355395B2 (ja) 2007-06-13 2013-11-27 大塚製薬株式会社 エクオール含有抽出物及びその製造方法、エクオール抽出方法、並びにエクオールを含む食品
CA2733907C (en) * 2008-08-15 2019-03-12 Nestec S.A. Use of soy isoflavones for enhancing metabolism in canines
US20110091435A1 (en) * 2008-10-24 2011-04-21 University Of Southern California Phytoestrogenic formulations for alleviation or prevention of hair loss
JP6140682B2 (ja) * 2011-04-15 2017-05-31 ネステク ソシエテ アノニム サーチュイン遺伝子発現の調節方法
CN103608011A (zh) * 2011-04-20 2014-02-26 雀巢产品技术援助有限公司 适合于预防和治疗高瘦素血症的方法和组合物
KR20160026042A (ko) * 2014-08-29 2016-03-09 (주)아모레퍼시픽 락토비온산을 함유하는 항스트레스용 또는 항상성 유지용 조성물
EP3207034B1 (en) * 2014-10-14 2023-06-07 Richard L. Jackson Anhydrous crystalline form of s-equol
AU2017301596A1 (en) * 2016-07-26 2019-02-07 Ausio Pharmaceuticals, Llc Methods of diagnosing and treating Alzheimer's disease with S-equol
EP3843718A1 (en) 2018-06-15 2021-07-07 The Board Of Regents Of The University Of Texas System Methods of treating and preventing melanoma with s-equol
WO2019240871A1 (en) 2018-06-15 2019-12-19 The Board Of Regents Of The University Of Texas System Methods of treating and preventing breast cancer with s-equol
AU2021259858B2 (en) * 2020-04-23 2024-12-19 University Of Iowa Research Foundation GPER proteolytic targeting chimeras
WO2021235278A1 (ja) * 2020-05-21 2021-11-25 株式会社ダイセル 閉経後で更年期障害を有しない満４０歳以上の女性のためのｑｏｌ改善用組成物
WO2022050308A1 (ja) * 2020-09-04 2022-03-10 株式会社ダイセル Ｎａｍｐｔ遺伝子発現増強用組成物
CN116531393A (zh) * 2023-04-03 2023-08-04 河北医科大学 一种预防高热惊厥发作的药物组合物
JP7596493B1 (ja) 2023-11-24 2024-12-09 株式会社ダイセル 男性のｑｏｌの改善のための組成物

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4390559A (en) * 1979-04-11 1983-06-28 Z-L Limited Partnership Isoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same
US5468501A (en) 1982-09-01 1995-11-21 Hercon Laboratories Corporation Article useful for administration of pharmacologically-active substances transdermally, orally or by means of implant
USRE34457E (en) * 1983-12-28 1993-11-30 Daicel Chemical Industries, Inc. Separating agent
GB8626344D0 (en) * 1986-11-04 1986-12-03 Zyma Sa Bicyclic compounds
JPH02124883A (ja) 1988-11-04 1990-05-14 Kitasato Inst:The 抗酸化作用を有するイソフラボン誘導体およびその製造法
CH679584A5 (cg-RX-API-DMAC7.html) * 1989-11-10 1992-03-13 Nestle Sa
TW279133B (cg-RX-API-DMAC7.html) 1990-12-13 1996-06-21 Elan Med Tech
PT656786E (pt) * 1992-05-19 2004-11-30 Novogen Res Pty Ltd Utilizacao de extractos do fitoestrogenio isoflavona de soja ou trevo
CA2160371A1 (en) * 1993-04-16 1994-10-27 The Trustees Of Tufts College Method for treatment of menopausal and premenstrual symptoms
US5613958A (en) 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
US5320949A (en) * 1993-10-12 1994-06-14 Protein Technologies International, Inc. Process for producing aglucone isoflavone enriched vegetable protein fiber
US5424331A (en) * 1994-06-10 1995-06-13 Bio-Virus Research Incorporated Pharmaceutical compositions and dietary soybean food products for the prevention of osteoporosis
AU3689095A (en) 1994-10-03 1996-04-26 Schouten Industries B.V. Food and health products
US5523087A (en) * 1995-02-15 1996-06-04 Bio-Virus Research Incorporated Pharmaceutical compositions for the treatment of diabetic male sexual dysfunction
AUPN166195A0 (en) * 1995-03-13 1995-04-06 Norvet Research Pty Limited Process for glucan extraction
FR2731706B1 (fr) * 1995-03-14 1997-04-11 Cird Galderma Composes heterocycliques aromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
US5554519A (en) 1995-08-07 1996-09-10 Fermalogic, Inc. Process of preparing genistein
US5693018A (en) 1995-10-11 1997-12-02 Science Incorporated Subdermal delivery device
US5821361A (en) * 1996-06-11 1998-10-13 Protein Technologies International, Inc. Recovery of isoflavones from soy molasses
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
US5726034A (en) * 1996-09-06 1998-03-10 Protein Technologies International, Inc. Aglucone isoflavone enriched vegetable protein extract and protein material, and high genistein and daidzein content materials and process for producing the same
US6020471A (en) * 1996-09-13 2000-02-01 Abbott Laboratories Process for isolating phytoestrogens from plant protein
US5804234A (en) * 1996-09-13 1998-09-08 Suh; John D. Plant protein for nutritional products and method of making same
WO1998021946A1 (en) 1996-11-18 1998-05-28 Internutria, Inc. Composition and treatment for persistent reproductive transition symptoms
US5733926A (en) * 1996-12-13 1998-03-31 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions
AUPO427196A0 (en) * 1996-12-19 1997-01-23 University Of Sydney, The A method for preventing or controlling cataract
AU7165798A (en) * 1997-04-28 1998-11-24 Anticancer, Inc. Use of genistein and related compounds to treat certain sex hormone related conditions
US6146668A (en) * 1997-04-28 2000-11-14 Novogen, Inc. Preparation of isoflavones from legumes
JP2001523258A (ja) * 1997-05-01 2001-11-20 ノボゲン インコーポレイテッド 更年期症状および骨粗鬆症の治療または予防
US6083526A (en) 1997-05-22 2000-07-04 Gorbach; Sherwood L. Use of isoflavonoids in the treatment or prevention of postpartum depression
US6060070A (en) * 1997-06-11 2000-05-09 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of aging skin and wrinkles
EP1025850B1 (en) * 1997-08-08 2005-11-23 Otsuka Pharmaceutical Co., Ltd. Isoflavone-containing compositions
US6521433B1 (en) * 1997-09-17 2003-02-18 E. I. Du Pont De Nemours And Company cDNA sequences from plants that encode activities associated with isoflavone biosynthesis
US5855892A (en) * 1997-09-19 1999-01-05 Potter; Susan M. Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease
US5952374A (en) * 1997-09-29 1999-09-14 Protein Technologies International, Inc. Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function
US5942539A (en) * 1997-10-03 1999-08-24 Wake Forest University Methods of treating or preventing endometriosis with phytoestrogens
AUPP112497A0 (en) * 1997-12-24 1998-01-22 Novogen Research Pty Ltd Compositions and method for protecting skin from UV induced immunosupression and skin damage
US5958946A (en) 1998-01-20 1999-09-28 Styczynski; Peter Modulation of hair growth
US6004558A (en) * 1998-02-25 1999-12-21 Novogen, Inc. Methods for treating cancer with legume plant extracts
AUPP260798A0 (en) * 1998-03-26 1998-04-23 Novogen Research Pty Ltd Treatment of medical related conditions with isoflavone containing extracts of clover
US6086915A (en) 1998-04-01 2000-07-11 Bioresponse L.L.C. Compositions and methods of adjusting steroid hormone metabolism through phytochemicals
CA2333556A1 (en) 1998-05-27 1999-12-02 Sherwood L. Gorbach Isoflavonoids for treatment and prevention of migraine headaches
WO2000013661A1 (en) 1998-09-10 2000-03-16 Avon Products, Inc. Method and compositions for reducing dermatological aging and for reducing bruising
HK1041636A1 (zh) 1998-11-25 2002-07-19 Nutri Pharma Asa 含大豆蛋白、食用纤维及植物性雌激素混合物的成份，以及使用上述成份预防及/或治疗第二类糖尿病、新陈代谢综合症及有关的心血管疾病
ATE242638T1 (de) * 1998-11-25 2003-06-15 Nutri Pharma As Verwendung einer zusammensetzung enthaltend sojaprotein, diätfasern und phytoestrogen zur vorbeugung und/oder behandlung von lungenerkrankungen
EP1146798A2 (en) 1999-01-15 2001-10-24 Nutrahealth Ltd. (UK) Modified food products and beverages, and additives for food and beverages
AUPP868599A0 (en) 1999-02-15 1999-03-11 Novogen Research Pty Ltd Production of isoflavone derivatives
EP1173164A2 (en) 1999-04-16 2002-01-23 AstraZeneca AB Estrogen receptor-beta ligands
AU777254B2 (en) 1999-04-20 2004-10-07 Board Of Trustees Of Southern Illinois University, The Methods of treating clinical diseases with isoflavones
US6544566B1 (en) * 1999-04-23 2003-04-08 Protein Technologies International, Inc. Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol
MXPA01011291A (es) 1999-05-04 2003-07-14 American Home Prod Derivados de urea ciclica y amida ciclica.
US6159959A (en) * 1999-05-06 2000-12-12 American Home Products Corporation Combined estrogen and antiestrogen therapy
US6401125B1 (en) 1999-08-05 2002-06-04 Nextpage, Inc. System and method for maintaining state information between a web proxy server and its clients
US6375994B1 (en) * 1999-08-20 2002-04-23 Sun Ten Laboratories, Inc. Preparation of fiber, L-glutamine and a soy derivative for the purpose of enhancement of isoflavone bioavailability
CA2416796A1 (en) * 2000-06-14 2001-12-20 Alla Shapiro Radioprotective agents
WO2002003976A2 (en) 2000-07-06 2002-01-17 Wyeth Combinations of bisphosphonates, estrogenic agents and optionally estrogens
WO2002003992A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating prosthesis-related bone degeneration
BR0112365A (pt) 2000-07-06 2003-05-13 Wyeth Corp Combinações de estatinas, agentes estrogênicos e opcionalmente estrogênios
US6455568B2 (en) * 2000-07-06 2002-09-24 Wyeth Combination therapy for inhibiting sphincter incontinence
AU2001283322A1 (en) 2000-08-10 2002-02-18 M. D. Brian D. Zelickson Organic nutrient for hair loss treatment
US6326366B1 (en) * 2000-08-22 2001-12-04 Protein Technologies International Hormone replacement therapy
US6565864B2 (en) * 2000-12-28 2003-05-20 Unilever Home & Personal Care Usa, A Division Of Conopco, Inc. Skin care product containing retinoids and phytoestrogens in a dual compartment package
US20020143059A1 (en) 2000-12-28 2002-10-03 Sreekumar Pillai Skin care product containing retinoids, retinoid booster and phytoestrogens in a dual compartment package
ATE556155T1 (de) * 2001-02-02 2012-05-15 Cons Eng Co Inc Verfahren zur herstellung und wärmebehandlung einer mehrzahl von metallgusteilen
US20020192310A1 (en) 2001-02-02 2002-12-19 Bland Jeffrey S. Medical composition for managing hormone balance
EP1234572B1 (de) * 2001-02-26 2013-10-30 Mibelle AG Cosmetics Isoflavon-Aglykone enhaltende Hautbehandlungsmittel
US6638543B2 (en) 2001-02-27 2003-10-28 Regents Of The University Of Michigan Use of natural EGFR inhibitors to prevent side effects due to retinoid therapy, soaps, and other stimuli that activate the epidermal growth factor receptor
DE10121375B4 (de) 2001-05-02 2014-01-16 Beiersdorf Ag Verwendung von Isoflavonoiden in kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe vor und Behandlung von sensibler Haut
DE10122342A1 (de) 2001-05-09 2002-11-14 Beiersdorf Ag Verwendung von Isoflavonen in kosmetischen oder dermatologischen Zubereitungen
FR2825277B1 (fr) 2001-05-30 2004-10-15 Oreal Composition cosmetique et/ou dermatologique et/ou pharmaceutique contenant au moins un compose ihnibiteur de l'enzime 3, b-hsd
US6597597B2 (en) * 2001-11-13 2003-07-22 Hewlett-Packard Company Low temperature attaching process for MRAM components
AU2003259220C1 (en) * 2002-07-24 2017-08-24 Australian Health & Nutrition Association Limited Compositions and products containing enantiomeric equol, and methods for their making
US8668914B2 (en) 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
AU2002951271A0 (en) 2002-09-06 2002-09-19 Novogen Research Pty Ltd Repair of dna mutagenic damage
CA2499602A1 (en) 2002-09-23 2004-04-01 Graham Edmund Kelly Skin photoageing and actinic damage treatment
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
EP1569636B1 (en) 2002-10-29 2017-12-13 Colorado State University Research Foundation Use of equol for treating androgen mediated diseases
EP1740191A4 (en) 2004-04-28 2008-07-30 Univ Brigham Young USE OF EQUOL FOR THE TREATMENT OF SKIN DISEASES
US7528267B2 (en) 2005-08-01 2009-05-05 Girindus America, Inc. Method for enantioselective hydrogenation of chromenes
CA2631850C (en) 2005-12-06 2015-02-24 Otsuka Pharmaceutical Co., Ltd. Equol-containing fermentation product of soybean embryonic axis, and method for production thereof

Similar Documents

Publication Publication Date Title
JP2012021005A5 (cg-RX-API-DMAC7.html)
Jaimes III et al. Plastics and cardiovascular health: phthalates may disrupt heart rate variability and cardiovascular reactivity
JP2012512907A5 (cg-RX-API-DMAC7.html)
CY1119575T1 (el) Ενωσεις υποκατεστημενης βενζαλδεϋδης και μεθοδοι για τη χρηση τους στην αυξηση της οξυγονωσης του ιστου
EP2205231A1 (en) Pharmaceutical compositions of 5-hydr0xytrypt0phan and serotonin-enhancing compound
BR112013025517A2 (pt) uso de 2,3-diidroimidazo[1,2-c]quinazolinas substituídas
JP6403726B2 (ja) ブプレノルフィンおよびμ−オピオイド受容体アンタゴニストの組成物
JP2015514104A5 (cg-RX-API-DMAC7.html)
JP2014508752A5 (cg-RX-API-DMAC7.html)
JP2010530431A5 (cg-RX-API-DMAC7.html)
WO2012087742A3 (en) Methods and compositions suitable for managing blood glucose in animals
JP2014517008A5 (cg-RX-API-DMAC7.html)
JP2016517888A5 (cg-RX-API-DMAC7.html)
JP2011500690A5 (cg-RX-API-DMAC7.html)
RU2012134510A (ru) Применение агента, обладающего модифицирующими свойствами в отношении гормонов надпочечников
JP2016510326A5 (cg-RX-API-DMAC7.html)
JP2013522230A5 (cg-RX-API-DMAC7.html)
JP2018526407A5 (cg-RX-API-DMAC7.html)
JP2014513065A5 (cg-RX-API-DMAC7.html)
JP2011046708A5 (cg-RX-API-DMAC7.html)
JP2017514858A5 (cg-RX-API-DMAC7.html)
Holder et al. The importance of biological sex in cardiac cachexia
CA2721739C (en) Drug combination and its use in the treatment of muscle loss
Li et al. Oleanolic acid protects against diabetic cardiomyopathy via modulation of the nuclear factor erythroid 2 and insulin signaling pathways
JP2014513121A5 (cg-RX-API-DMAC7.html)